BURLINGTON, Mass., Dec. 13, 2011 /PRNewswire/ -- Coronado Biosciences, Inc., (OTCBB: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of ...
Coronado Biosciences announced the initiation of a phase 1/2 dose escalation trial of allogeneic natural killer, or NK, cells activated by the Company's CNDO-109 in patients in first complete ...
Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies Current data highlight the potential role for immunotherapy in AML. Gaps in knowledge include limited studies on ...
BURLINGTON, Mass., Dec. 8, 2011 /PRNewswire/ -- Coronado Biosciences, Inc., (OTCBB: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results